<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OPINION STATEMENT: Idiopathic intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> (IIH, <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri</z:e>) is a syndrome of <z:e sem="disease" ids="C0151740" disease_type="Disease or Syndrome" abbrv="">elevated intracranial pressure</z:e> of unknown cause that occurs predominantly in <z:mp ids='MP_0001261'>obese</z:mp> women of childbearing age </plain></SENT>
<SENT sid="1" pm="."><plain>It is a diagnosis of exclusion and, therefore, other causes of <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo> must be sought with history, imaging, and cerebrospinal fluid examination before the diagnosis can be made </plain></SENT>
<SENT sid="2" pm="."><plain>IIH produces symptoms and signs of <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo>, including <z:hpo ids='HP_0001085'>papilledema</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>If untreated, <z:hpo ids='HP_0001085'>papilledema</z:hpo> can cause progressive irreversible <z:hpo ids='HP_0000572'>visual loss</z:hpo> and <z:hpo ids='HP_0000648'>optic atrophy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The treatment approach depends on the severity and time course of symptoms and <z:hpo ids='HP_0000572'>visual loss</z:hpo>, as determined by formal visual field testing </plain></SENT>
<SENT sid="5" pm="."><plain>The main goals of treatment are alleviation of symptoms, including <z:hpo ids='HP_0002315'>headache</z:hpo>, and preservation of vision </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> overweight IIH patients should be encouraged to enter a weight-management program with a goal of 5-10Â % <z:hpo ids='HP_0001824'>weight loss</z:hpo>, along with a low-salt diet </plain></SENT>
<SENT sid="7" pm="."><plain>When there is mild <z:hpo ids='HP_0000572'>visual loss</z:hpo>, medical treatment with <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> should be initiated </plain></SENT>
<SENT sid="8" pm="."><plain>Other medical treatments can be added or substituted when <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> is insufficient as monotherapy or poorly tolerated </plain></SENT>
<SENT sid="9" pm="."><plain>When <z:hpo ids='HP_0000572'>visual loss</z:hpo> is more severe or <z:hpo ids='HP_0003678'>rapidly progressive</z:hpo>, surgical interventions, such as optic nerve sheath fenestration or cerebrospinal fluid shunting, may be required to prevent further irreversible <z:hpo ids='HP_0000572'>visual loss</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>The choice of intervention depends on the relative severity of symptoms and <z:hpo ids='HP_0000572'>visual loss</z:hpo>, as well as local expertise </plain></SENT>
<SENT sid="11" pm="."><plain>At present, the role of transverse venous sinus stenting remains unclear </plain></SENT>
<SENT sid="12" pm="."><plain>Although there are no evidence-based data to guide therapy, there is an ongoing randomized double-blind placebo-controlled treatment trial, investigating diet and <z:chebi fb="0" ids="27690">acetazolamide</z:chebi> therapy for IIH </plain></SENT>
</text></document>